Abstract
Matrix metalloproteinase (MMP)-12 (or metalloelastase) efficiently hydrolyzed the gelatinase-selective α1(V)436-447 fluorescent triple helical peptide (THP) when the substrate was submicromolar. The sequence of this THP was derived from collagen V, a component of collagen I fibrils. The hemopexin domains of MMP-12 and -9 each increased kcat/Km toward this substrate by decreasing Km, just as the hemopexin domain of MMP-1 enhances its triple helical peptidase activity. Non-fluorescent α1(V) THP subtly perturbed amide NMR chemical shifts of MMP-12 not only in the active site cleft but also at remote sites of the β-sheet and adjoining loops. The α1(V) THP protected MMP-12 from the NMR line broadening effects of Gd ·EDTA in the active site cleft and more dramatically in the V-B loop next to the primed subsites. Mutagenesis of the exosite in the V-B loop at Thr-205 and His-206 that vary among MMP sequences established that this site supports the high specific activity toward α1(V) fluorescent THP without affecting general MMP activity. Surprisingly the α1(V) THP also protected novel surfaces in the S-shaped metal-binding loop and β-strands III and V that together form a pocket on the remote side of the zinc binding site. The patterns of protection suggest bending of the triple helical peptide partly around the catalytic domain to reach novel exosites. Partial unwinding or underwinding of the triple helix could accompany this to facilitate its hydrolysis.
Collagens are principal constituents of connective tissues. They are hydrolyzed during development, wound repair, and remodeling of the extracellular matrix. Dysregulated collagenolysis is active in inflammatory diseases such as atherosclerosis, cancer, rheumatoid arthritis, periodontitis, and liver and kidney pathologies. Matrix metalloproteinases (MMPs)3 play key roles in these processes (1-3). Mutagenesis has established the importance of the V-B loop (joining β-strand V and helix B) in collagenolysis by MMP-1 (4). Residues at the C-terminal end of this loop in MMP-8 were also implicated in collagenolysis (5) and triple helical peptidase activity (6). Binding of an inactivated MMP-1 to an intact collagen fibril likely unwinds the triple helix at the cleavage site to provide access for an active MMP-1 catalytic domain to hydrolyze individual chains (7). The direction of collagen triple helices at the active site is unknown, but the orientation can be hypothesized to be the same as in linear peptide substrates that run antiparallel to β-strand IV (8, 9). Single chain peptides from the α1 chain of type I/III collagens were soaked into crystals of MMP-12 and MMP-8 catalytic domains, and snapshots of bound hydrolysis products were obtained (8). However, neither crystallography nor NMR data representative of interactions with collagen have been reported because of technical limitations. More generally, structural studies of complexes of enzymes with their substrates have been rare presumably because of catalytic turnover and affinities lower than those for transition state analogues.
Several biologically active, self-assembling triple helical peptide (THP) mimics of collagens have been developed. These THPs have facilitated numerous biochemical and cell biological studies otherwise infeasible with insoluble, intact collagen fibrils. THPs are successful in reproducing the cleavage sites of MMPs in collagens I, II, III, V, and XI and in reproducing rate dependences on intact triple helical structure (10, 11). Fluorogenic labeling of THPs has facilitated quantitative comparisons of the triple helical peptidase activities of a variety of MMPs in solution and in cell culture assay (6, 11, 12). The affinities of MMP catalytic domains for triple helices range from 1 to 80 μm (6, 11-13). Collagenolysis involves several MMP functions that include initial nonspecific binding and orientation of collagen fibrils (14, 15), manipulation of collagen fibrils with the C-terminal hemopexin domain (16) and catalytic domain (7), unwinding of triple helices within fibrils, and ensuing hydrolysis of single chains from the melted triple helix (7). THPs are not suitable for modeling the initial binding, orientation, and manipulation of full-length collagen assembled into large, insoluble fibrils (6, 11). They are too small to participate in these higher order events (7). Nonetheless THPs have proven themselves to be outstanding substrates for detailed characterization of the triple helical peptidase activities of MMPs and other metalloproteinases (6, 11, 17, 18). This activity includes localized unwinding of the collagen triple helix and hydrolysis of the exposed single strands (6, 11).
MMP-dependent hydrolysis of collagens is a hallmark of inflamed and vulnerable atheromatous plaques (19-21), which are rich in macrophages (21). Macrophages secrete MMP-12 at sites of inflammation (22-24). MMP-12 has emerged as a drug target for atherosclerosis because specific inhibition of it is expected to stabilize atherosclerotic plaques and prevent ruptures that precipitate heart attack and stroke (23, 25, 26). This protease also exacerbates inflammatory arthritis (27) where collagenolysis is well known. The active form of MMP-12 (also called macrophage metalloelastase) observed in situ consists of its catalytic domain apparently after autolytic loss of the C-terminal hemopexin domain (28). Numerous x-ray and NMR structures of complexes of MMPs with small inhibitors are available (29), including several of MMP-12 (9, 30-35). Attempts at crystallizing an MMP with THP bound may have been stymied by moderate affinities of MMPs for THPs and complexities of the binding modes of the THPs. The solution structure of MMP-12 with the active site vacant but inactivated by the E219A mutation was recently determined for supporting studies of substrate interactions (36). The moderate Km values of MMPs for THPs suggest that NMR can be a worthwhile avenue to interaction studies because NMR methods accommodate moderate affinities and transient associations (37).
Type I collagen fibrils in most connective tissues are copolymerized with fibrillar type V collagen that is buried within the fibrils and present, for example, at 15-20% in cornea (38-41). Increasing collagen V content decreases the diameter of collagen I fibrils (38). Type V and XI collagens resist collagenases (42) but are sensitive to gelatinases (43-45). The gelatinase MMP-9 cleaves collagen chains α1(V) and α(XI) between Gly-439 and Val-440 and the α2(V) chain between Gly-445 and Leu-446 (46). The α1(V)436-447 fTHP substrate mimics the former cleavage site and is selectively hydrolyzed by the gelatinases MMP-2 and MMP-9. MMP-1, -3, -13, and -14 fail to hydrolyze this THP (11). We found MMP-12 to hydrolyze this “gelatinase-specific” substrate readily at submicromolar concentrations with activity comparable to that of MMP-2 and MMP-9. MMP-12 achieved this even though it lacks fibronectin modules to assist. We applied an NMR footprinting method to map sites of α1(V)436-450 THP protection of MMP-12 from the paramagnetic probe of Gd ·EDTA. This NMR method has accurately mapped interfaces of protein-protein complexes with affinities ranging from 3 nm (47, 48) to about 10 μm (49, 50) and has successfully guided mutagenesis to an unexpected “hot spot” in a protein-protein interface (50). NMR mapping identified THP contacts not only around the MMP-12 active site but also at THP-protected exosites on the β-sheet, the S-shaped cation-binding III-IV loop, and V-B loop. NMR-guided mutagenesis (50) of the V-B loop indicated that Thr-205 and His-206 form a site critical for affinity (Km) and specific activity for the α1(V) THP without affecting activity upon a general MMP substrate. Implications of the unexpected pattern of α1(V) THP protection of the MMP-12 catalytic domain are discussed.
EXPERIMENTAL PROCEDURES
Sample Preparation for Kinetic Analysis—The catalytic domain of human MMP-12 was prepared as a 164-residue construct as described previously (51) and used for kinetic analyses. All kinetic experiments using MMP-12 were performed in an assay buffer of 50 mm Tricine (pH 7.5) containing 100 mm NaCl, 10 mm CaCl2, 0.1 mm ZnCl2, 0.05% Brij-35, and 0.02% sodium azide. α1(V)436-447 fTHP, with a C6 (hexanoate) substituent at each N terminus, was first dissolved to ∼10 mm in high purity, anhydrous DMSO. Stock solutions of α1(V)436-447 fTHP were prepared at 210 μm in assay buffer. The working stock of α1(V)436-447 fTHP was serially diluted from 20- to 1000-fold further in the assay buffer. DMSO always remained less than 0.1% in the assay itself. The wt MMP-12 catalytic domain was kept as a storage stock solution of 9.59 μm in 50% glycerol, frozen at -80 °C. The working stock solution of 500 nm wt MMP-12 catalytic domain was prepared in assay buffer just prior to analysis. Assays typically used wt MMP-12 at 100 nm. Site-directed mutations were introduced to wt MMP-12 using the QuikChange mutagenesis kit (Stratagene). DNA sequencing confirmed the mutations and the absence of stray mutations elsewhere.
Kinetics and Sites of Proteolysis—For accuracy, the concentration [E0] of intact protease active sites was measured (52) using galardin (GM6001) (53). The observed rate kobs was measured from a single progress curve under first order conditions where [S0] ≪ Km (54, 55). These two measurements then provided the second order rate constant from the relationship kcat/Km = kobs/[E0] (54, 55). The preferred way to obtain kcat and Km was to use a new procedure of globally fitting two or more progress curves, saving time, substrate, and concern about fluorescence attenuation by the inner filter effect (51). The plateau in relative fluorescence units (RFU) reached within the 1st h of the reaction was used to convert between ΔRFU and substrate concentration. In cases where part of the α1(V) fTHP remains unhydrolyzed, the concentration of α1(V) fTHP hydrolyzed and apparent kcat may be overestimated compared with explicit evaluation of total hydrolysis. MMP substrate cleavage sites were established by MALDI-TOF mass spectrometry with an Applied Biosystems Voyager DE-STR MALDI-TOF mass spectrometer using an α-cyano-4-hydroxycinnamic acid matrix. The substrate used to monitor general metalloprotease activity is FS-6 (Mca-Lys-Pro-Leu-Gly-Leu-Lys(Dnp)-Ala-Arg-NH2), which possesses greater solubility than its predecessor, Knight's substrate (55).
Samples for NMR Spectroscopy—MMP-12 was expressed with the inactivating alanine substitution of the glutamate general base (9, 56, 57), i.e. E219A. This mutation enables NMR studies of MMP-12 without turnover of substrate, without inhibitor, and without autolysis (36, 58). The lack of structural perturbation by the mutation beyond the side chain itself is evident from comparison of crystal structures (9, 30) and from the minimal and localized chemical shift perturbations of NMR spectra (36). Recombinant E219A-inactivated catalytic domain was prepared as described previously (36, 58, 59). Uniformly 15N-labeled MMP-12(E219A) was expressed (51) in an Escherichia coli BL21(DE3) RIL host using 15NH4CI-based M9 medium supplemented with Celtone (Spectral Stable Isotopes) at 20% (v/v). Samples of 15N-labeled MMP-12 were prepared for NMR typically at 0.6 mm with 20 mm imidazole at pH 6.6, 10 mm CaCl2, 20 μm ZnCl2, 1 mm sodium azide, and 90% H2O, 10% D2O.
NMR Spectroscopy—NMR spectra and titrations were acquired at 26 °C on a Varian Inova 600-MHz spectrometer equipped with a high sensitivity 5-mm cryogenic HCN triple resonance probe with an actively shielded z-gradient coil. NMRPipe (60) was used to process NMR spectra. Sparky (61) was used to analyze spectra. The fast heteronuclear single quantum correlation approach (62) was used to minimize saturation of the water resonance. Spectral acquisitions used TROSY for its 15N line sharpening and decreased overlap (63). To recognize the affinity for α1(V)436-450 THP and sites it affects in 15N-labeled MMP-12(E219A), the perturbations of amide NMR chemical shifts by THP were monitored. For more accurate mapping of the residues in the interface, α1(V) THP protection of MMP-12(E219A) residues from paramagnetic line broadening by inert EDTA-chelated Gd(III) was monitored (47, 48, 50).
NMR Titrations for Affinity and Perturbations of α1(V) THP—Stock solutions of α1(V)436-450 THP were dissolved in the NMR buffer, adjusted to pH 6.6, and determined to be 7-8 mm by quantitative amino acid analysis. For identifying amide groups of MMP-12(E219A) that respond to the binding of α1(V)436-450 THP, 15N TROSY spectra in the absence and in the presence of a 1.5-fold molar excess of α1(V) THP were compared for changes in amide 1H and 15N chemical shifts. To measure the affinity of the association, a series of 15N TROSY spectra were collected with progressive additions of this α1(V) THP to attain molar ratios of 15N-labeled MMP-12 to the α1(V) THP of 1:0, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.6, 1:1, and 1:1.5. The chemical shift changes of affected MMP-12 residues were plotted against total [α1(V) THP] and fitted by non-linear regression to the following equation (64, 65) to solve for KD,
![]() |
(Eq.1) |
where Pt and Lt are the total concentrations of the protein 15N-labeled MMP-12 and α1(V) THP ligand, respectively. δobs is the observed NMR peak position or chemical shift. δP and δPL are the chemical shifts of the free MMP-12 and the complex. Origin 7.5 (Microcal) was used to globally fit the binding isotherms from the 1H peak positions of all affected residues simultaneously.
NMR Mapping of Protection from Paramagnetic Gd ·EDTA—Stock solutions of Gd ·EDTA were adjusted to pH 6.6 before use. TROSY spectra of 15N-labeled MMP-12(E219A), both in the absence and presence of α1(V)436-450 THP, were collected with additions of 0, 1, 2, and 3 mm Gd ·EDTA. The line broadening effect from each addition of Gd ·EDTA was quantified by dividing the amide peak heights of each MMP-12 residue by the peak height without the addition. This normalized the NMR peak height with paramagnetic probe present to a scale from 0 (complete broadening and high surface exposure) to 1 (absence of broadening and considerable burial). The normalized peak heights could then be easily compared as the difference between the free state and that bound to α1(V) THP without complication by differences in sample concentrations or spectral acquisition parameters. The uncertainties in peak heights were estimated as the reciprocal of the signal to noise reported by the Sparky peak picking software (61) and then scaled up by 1.48-fold to represent ±1 S.D. These uncertainties were incorporated into the normalized peak heights and their differences between bound and free states using the standard rules of error propagation.
Modeling of Complex of MMP-12 with THP—The triple helical peptide was initially represented by the crystal structure of the triple helical peptide from the collagenase cleavage site in collagen III (Protein Data Bank code 1BKV)(66) comprising 30-residue chains. This structure was docked by hand with the NMR structure of ligand-free MMP-12 (Protein Data Bank code 2POJ) (36) in MolMol (67). Using DeepView (68), the individual chains of the THP were rotated, one backbone torsion angle at a time, to bend the chains over surfaces of MMP-12 protected by α1(V)436-450 THP from Gd ·EDTA. Each structural figure was rendered with PyMol (69).
RESULTS AND DISCUSSION
Activity of MMP-12 upon THP Mimic of Collagen V—The ability of MMP-12 to hydrolyze THP substrates of other MMPs was investigated. α1(V)436-447 fTHP, derived from the site of MMP-9 cleavage in fibrillar collagen V (11, 46), was efficiently hydrolyzed by MMP-12. (Because the mature form of active MMP-12 observed physiologically is autolytically truncated to the 22-kDa catalytic domain (28), we refer to the catalytic domain as MMP-12.) MMP-12 activity toward α1(V)436-447 fTHP at 30 °C exhibited an apparent kcat/Km of 97,600 ± 3,200 m -1 s-1, a Km of 24.8 μm, and an apparent kcat of 2.35 s-1 (Fig. 1A and Table 1). Progress curves fitted to steady-state kinetics parameters using a new expedited analysis (51) are drawn in Fig. 1B for reactions at 25 °C. Arrhenius plotting of the temperature dependence of the second order rate constant kcat/Km (Table 1) suggested an activation barrier of 13.7 kcal/mol (Fig. 1C). This is comparable to the activation energies of collagenases with THP substrates (70, 71). Fits of steady-state kinetics parameters to progress curves for the digestion of α1(V)436-447 fTHP by full-length MMP-12, -9, or -2 or by MMP-9 catalytic domain are depicted in supplemental Fig. S1. The apparent kcat/Km of MMP-12 toward α1(V)436-447 fTHP was 60% of that of the MMP-9 catalytic domain (Table 1). The kcat/Km of full-length MMP-12 of 389,500 m-1 s-1 was 4.0-fold higher than that of the catalytic domain mainly because the Km dropped almost 3-fold to 8.4 μm, although the apparent kcat was also enhanced to 3.3 s-1 (Table 1). The kcat/Km of full-length MMP-12 was 85 and 103% that of full-length MMP-2 and MMP-9, respectively (Table 1). The gelatinases apparently have better affinity for the collagen V-derived THP than does MMP-12 judging from their Km values that were lower by a few-fold. Analogous to MMP-12, the C-terminal hemopexin domain of MMP-9 boosted catalytic efficiency by 2.4-fold largely because of the 2-fold better Km. The presence of the C-terminal hemopexin domain of MMP-1 was shown previously to enhance kcat/Km for triple helical substrates such as α1(I)772-786 THP by 1.33-fold by improving Km (10) and fTHP-4 by 2.6-fold by improving kcat (13). Thus, the C-terminal hemopexin domain confers more efficient association and hydrolysis of triple helical substrates in the cases of MMP-1, -9, and -12 that have been tested.
FIGURE 1.
Analysis of MMP-12 activity toward α1(V)436-447 fTHP. Steady-state kinetics results were obtained from initial velocities at 30 °C with 7.8 nm MMP-12 (A) and using expedited analysis of progress curves (51) at 25 °C with 10 nm MMP-12 (B). The shorter progress curve in B, marked with triangles, used a different preparation of the α1(V) fTHP. C shows an Arrhenius plot of the temperature dependence. RFU, relative fluorescence units.
TABLE 1.
Kinetic parameters for hydrolysis of α1(V)436-447 fTHP
| Proteasea | Temperature | kcat/Kmb | kcatc,d | Kmc |
|---|---|---|---|---|
| °C | M−1 S−1 | S−1 | μM | |
| MMP-12 cat | 25 | 55,400 ± 4,700 | 1.23 ± 0.10 | 22.2 ± 5.6 |
| MMP-12 cat | 30 | 97,600 ± 3,200 | 2.35 ± 0.2e | 24.8 ± 5.6e |
| MMP-12 cat | 37 | 145,300 ± 1,900 | NDf | ND |
| MMP-12 full | 30 | 389,500 ± 500 | 3.27 ± 0.08 | 8.4 ± 0.2 |
| MMP-9 cat | 30 | 156,400 ± 200 | 1.41 ± 0.05 | 9.0 ± 0.4 |
| MMP-9 full | 30 | 378,100 ± 490 | 1.67 ± 0.003 | 4.41 ± 0.01 |
| MMP-2 full | 30 | 459,700 ± 2,500 | 0.98 ± 0.01 | 2.13 ± 0.02 |
cat refers to catalytic domain; full refers to full length.
Derived from a few progress curves by the rapid method of Ref. 51.
An upper estimate in cases where some α1(V) fTHP remains unhydrolyzed once plateau in fluorescence is reached.
ND, not determined.
A lag phase of around 50 s took place before MMP-12 hydrolyzes α1(V)436-447 fTHP with the linear kinetics phase. The lag phase was around 4 s for MMP-9 constructs, and there was almost no lag phase for MMP-2. Each lag phase was removed prior to fitting steady-state kinetics (Table 1, Fig. 1, supplemental Fig. S1, and Fig. 6). The lengths of the lag phases appear to be independent of the concentration of either the MMP or the α1(V) fTHP. The longer lag phase of MMP-12 might reflect slower melting of the triple helix in advance of hydrolysis of the scissile bond. Perhaps interactions with fibronectin-like modules of the gelatinase hasten unwinding of the triple helix.
FIGURE 6.
3-Fold lower specific activity of MMP-12(T205K/H206D) for α1(V) THP. The progress curves were fitted by the expedited method of Ref. 51. Triangles and circles represent progress curves collected with 1 and 10 μm α1(V)436-447 fTHP, respectively, and 100 and 300 nm MMP-12, respectively. RFU, relative fluorescence units.
Non-fluorogenic α1(V)436-450 THP (C6-(GPO)4GPPG-VVGE↓QGEQ(GPO)4-NH2 where O represented was 4-hydroxyproline) was hydrolyzed by MMP-12 at the scissile bond indicated by the arrow. MALDI mass spectrometry supported this by way of the agreement of the measured mass of the N-terminal [M + Na]+ ion of 1922.5 Da with the theoretical mass of 1922.1 Da. Both MMP-12 and full-length MMP-12 mainly hydrolyze fluorogenic α1(V)436-447 fTHP at the analogous peptide bond marked by the underlined arrow in the following: C6-(GPO)5GEK(Mca)GPPG↓VVG↓E↓K(Dnp)GEQ(GPO)5-NH2. The additional arrows indicate linkages susceptible to MMP-2 or MMP-9 cleavage. The Glu↓Lys(Dnp) peptide bond appears to be the main site of hydrolysis by MMP-12 because the predominant peaks observed are (i) the N-terminal [M + Na]+ ion at 2665.8 Da coinciding with the theoretical mass of 2665.9 Da and (ii) the C-terminal [M + Na]+ ion of 1983.7 Da coinciding with the theoretical mass of 1984.0 Da. MMP-2 hydrolyzed this same site as evident from the C-terminal [M + Na]+ ion of 1984.8 Da observed. Yet MMP-2 also hydrolyzed the Gly↓Glu bond as indicated by the C-terminal fragment ion of 2113.9 Da (2113.1 Da theoretical) as well as the Gly-Val bond as indicated by both the C-terminal fragment ion of 2368.9 Da (2368.5 Da theoretical) and N-terminal fragment ion of 2281.8 Da (2281.5 Da theoretical). MMP-9 cleaved only the Gly↓Val bond in α1(V)436-447 fTHP that was equivalent to its cleavage site in type V collagen (46).
MMP-12 hydrolyzed fTHP-4, derived from a consensus of MMP cleavage sites in collagens I, II, and III (1); at 30 °C the apparent kcat/K is 59,000 ± 100 m-1 s-1, apparent kcat is 4.3 ± 0.2 s-1, and Km is 73 ± 3 μm. For comparison, MMP-9 catalytic domain much more rapidly hydrolyzed fTHP-4 with apparent kcat/Km of 3.20 × 106±1.2 × 105 m-1 s-1. MMP-12 hydrolyzed fluorescently labeled DQ-collagen I and DQ-collagen IV with apparent second order rate constant kcat/Km of the order of 30,000 m-1 s-1 each.4 MMP-12 hydrolyzes type V collagen (72), paralleling the gelatinases (43, 46). MMP-2 cleavage of collagen I (73) is similar to MMP-12 hydrolysis of DQ-collagen I.
α1(V) THP Perturbs Chemical Shifts of Sites across MMP-12(E219A)—We used NMR to map sites within E219A-inactivated MMP-12 affected by addition of non-fluorogenic α1(V)436-450 THP. The changes in backbone amide NMR chemical shifts of MMP-12(E219A) upon addition of a saturating amount (1.5 molar eq) of the α1(V) THP were measured as the radius of the changes, ΔωNH, from 15 N TROSY spectra (Fig. 2A). The largest chemical shift perturbations from α1(V) THP binding are 1-2 orders of magnitude smaller than the largest perturbations from inhibitor binding (see Ref. 36). This qualitatively correlates with the affinity of the α1(V) THP for MMP-12 being at least 3 orders of magnitude weaker than the affinity of inhibitors of MMPs. The residues sensitive to α1(V) THP binding span the full breadth of the active site cleft and extend well beyond the active site. A threshold of significant ΔωNH of 0.029 ppm captures several residues encompassing the heart of the active site of MMP-12 (Ala-182, Thr-210, Gly-221, His-222, Leu-224, Gly-225, Tyr-240, and Lys-241) and several residues further from the active site cleft (His-112, Tyr-113, Leu-146, Lys-147, Phe-174, Gly-188, Thr-205, Asp-244, and Asp-254) (Fig. 2). Lowering the threshold of significant ΔωNH to 0.022 ppm adds the following residues around the active site cleft: Gly-106 and Val-108 at the N terminus, Ala-184 and Phe-185 next to sIV, Gly-209 of the V-B loop, Phe-213 of hB, and Val-243 of the S1′ specificity loop or B-C loop (Fig. 2). (The nomenclature uses “s” for β-strand and “h” for α-helix (29). Loops are named by the flanking elements of secondary structure.) The residues outside the catalytic cleft with 0.029 ppm > ΔωNH ≥ 0.022 ppm are Ile-114 of sI, Val-161 and Val-162 of sIII, Gly-166 and His-172 of the III-IV loop, Asp-198 of sV, Thr-204 and His-206 of the V-B loop, Ile-245 of the S1′ specificity loop, and Ser-260 of hC (Fig. 2). The affected residues prior to sI mark one extreme of the active site cleft and its “unprimed” subsites (Fig. 2B, left). The affected residues of the V-B loop mark the other extreme of the cleft and “primed” subsites (Fig. 2B, right). ΔωNH perturbations from binding of α1(V) THP surprisingly were distributed to all of the secondary structures of MMP-12 except perhaps hA. A cluster of spectral perturbations from binding of α1(V) THP mapped to the N-terminal ends of sI and sII (His-112 to Leu-114 and Leu-147 to Lys-148), distant from the active site (Fig. 2B). This cluster coincides with inhibitor-induced chemical shift changes of His-112 and Lys-147 and an accompanying adjustment in the position of Arg-110 through Tyr-113 (36). Other THP-perturbed NMR peaks also mapped outside the active site to the III-IV loop that binds zinc and calcium, the IV-V loop, sV, and hC. Because inhibitors perturb equivalent remote sites in MMP-12, MMP-1, or MMP-3 (36), the subtle effects of binding of the α1(V) THP substrate could be similarly propagating through the same internal network proposed within MMP catalytic domains (36). The chemical shift perturbations of Val-161 and Val-162 in sIII by α1(V) THP also coincide with the chemical shift perturbations of Leu-160 through Phe-163 by inhibitors that may be related to the internal conformational adjustment that changes the distance between sIII and hB (36). However, a more likely cause of the perturbations of sIII is the protection of sIII by α1(V) THP presented below.
FIGURE 2.
α1(V) THP perturbation of the amide NMR chemical shifts of MMP-12(E219A). A quantifies the chemical shift changes from adding 1.5 molar eq of α1(V)436-450 THP as the radius of the change ΔωHN = [(ΔωH)2 + (ΔωN/5)2]1/2 relative to the NMR peak assignments of ligand-free MMP-12(E219A) (58). The factor of 5 normalizes the 15N ppm scale down to the 1H ppm scale. Cylinders mark the helices, and arrows mark the β-strands. B marks the α1(V) THP-dependent chemical shift changes above the threshold line of 0.029 ppm from A in red upon the ligand-free NMR structure of E219A-inactivated MMP-12 (Protein Data Bank code 2POJ, model 1) (36). Sites of chemical shift changes between 0.022 and 0.029 ppm are colored orange. Calcium ions are colored light gray, and zinc ions are medium gray. The arrow marks Thr-205 selected for mutagenesis.
Affinity of α1(V) THP for MMP-12(E219A) by NMR—The affinity of α1(V)436-450 THP for MMP-12(E219A) was investigated using the dependence of amide proton chemical shift ΔωH of MMP-12(E219A) on α1(V) THP concentration (Fig. 3).
FIGURE 3.
Binding isotherms for the association of MMP-12(E219A) with α1(V) THP. The 1H component of the amide NMR chemical shift perturbations by binding of α1(V)436-450 THP were measured from 15N TROSY spectra and fitted to the ligand saturation expression of Equation 1.
15N TROSY spectra were collected over a series of six progressively larger additions of α1(V) THP to 15N-labeled MMP-12(E219A). Binding isotherms were constructed from ΔωH increasing with α1(V) THP concentration until near saturation at about 1.5-fold molar excess (Fig. 3). The binding isotherms of 10 residues with largest ΔωH (His-112, Tyr-113, Leu-147, Lys-148, Thr-205, Thr-210, Gly-221, Leu-224, Tyr-240, and Val-243) were plotted and globally fitted together to the ligand binding expression of Equation 1 (Fig. 3). The global fit indicates that α1(V) THP binds 15N-labeled MMP-12(E219A) with a dissociation constant KD of 30 ± 6 μm (Fig. 3). This KD agrees within uncertainties with the Km values of steady-state turnover (Fig. 1). To further evaluate the significance of the α1(V) THP binding-induced changes in NMR chemical shifts inside and outside the active site cleft, the surface of MMP-12(E219A) occluded at its interfaces with the THP was probed.
α1(V) THP Protection of MMP-12(E219A) from Paramagnetic Probe—Binding sites on a protein can be mapped accurately using the protection of the binding site by its binding partner from the NMR line broadening effects of an inert paramagnetic probe (47, 48, 74). Protection from the paramagnetic probe avoids the misdirection of chemical shift perturbations occurring at a distance from the binding site or resulting from binding-linked conformational change (47, 75). Protection from the paramagnetic probe is cheaper and easier to implement than cross-saturation for accurate mapping of binding sites (74). Chelated Gd(III) is a most convenient paramagnetic probe that avoids the apparatus needed to use oxygen as the probe. Chelation makes Gd(III) a global probe of biomacromolecular surfaces. The Gd(III) causes strong 1H NMR line broadening of groups near the surface. Dividing the NMR peak height with Gd(III) chelate present by the peak height without it gives a quantity ranging from 1.0 for a buried proton lacking line broadening by distant Gd(III) to 0.0 for an exposed proton with a peak broadened beyond detection by Gd(III). This line broadening parameter is compared with binding partner present and absent as illustrated in supplemental Fig. S2. Sites that are significantly less broadened in the bound state probably lie occluded in the interface. Because the method has been effective for associations with KD in the range of 10 μm (49, 50), it is suitable for MMP associations with THPs.
We collected TROSY spectra of E219A-inactivated MMP-12 with 0, 1, 2, or 3 mm Gd ·EDTA probe both without and with a 1.5-fold molar excess of α1(V)436-450 THP present. Most loops and termini were exposed enough that I1 mM/I0 is <0.4 (Fig. 4A). Several sites were virtually completely broadened away by 1 mm Gd ·EDTA, implying their high exposure. These highly exposed sites in secondary structures were Asn-126 to Asp-131 of hA, Lys-151 of sII, and Ala-252, Asp-253, and Gly-263 at either end of hC (Fig. 4A). The highly exposed sites in loops included Gly-193 and His-228 to Ala-234. Least exposed to the line broadening probe according to highest I1 mM/I0 were β-strands sI, sIII, and sV in the interior of the β-sheet, surprisingly sIV on the edge of the sheet, the C-terminal end of hA around Val-140, and His-218 to Ser-223 of hB (Fig. 4A) where two histidines coordinate the zinc in the active site.
FIGURE 4.
Exposure of the backbone of MMP-12(E219A) to line broadening by Gd·EDTA probe in the absence and presence of α1(V) THP. The α1(V)436-450 THP was added to 1.5-fold molar excess. Amide NMR peak heights of MMP-12 with 1 mm Gd ·EDTA present, I1 m, are normalized by the peak heights without addition of the probe, I0. The normalized ratios, I1 m/I0, on a scale of 0 to 1, are readily compared between the free (A) and THP-bound states (B) as the difference in C. THP-bound minus free differences, I1 m/I0,+THP - I1 m/I0, free, >0.4 are considered large protections from the probe by α1(V) THP. Differences where 0.4 > I1 m/I0,+THP - I1 m/I0, free > 0.15 are considered medium-sized protections by α1(V) THP. Cylinders mark the helices, and arrows mark the β-strands.
Once the saturating, 1.5-fold molar excess of α1(V)436-450 THP was added, values of I1 mM/I0 were increased significantly for more than 30 residues, especially from Val-161 through Tyr-240 (Fig. 4B). This indicates the greater burial and protection of these residues by the α1(V) THP from the line broadening probe. The greatest protection has I1 mM/I0,+THP-I1 mM/I0, free > 0.4 and occurred predominantly in the S-shaped III-IV loop and the V-B loop (Fig. 4C). Neighboring Asp-124 (I-A loop), Ala-164 (sIII), and Phe-197 (sV) were also highly protected (Fig. 4C). Protection was also clearly significant for residues with 0.4 > I1 mM/I0,+THP-I1 mM/I0, free > 0.15 as observed for hB, Gly-227, Thr-239, and Tyr-240 at the active site cleft as expected (Figs. 4C and 5). (This lower threshold is conservative considering that a number of residues had base-line values of I1 mM/I0,+THP-I1 mM/I0, free < 0, beyond the uncertainties in Fig. 4C.) The negative values are consistent with the greater broadening expected for a complex because its slower tumbling enhances the paramagnetic line broadening (47).) Results with 2 or 3 mm Gd ·EDTA probe manifested similar patterns of protection as at 1 mm. Increasing [Gd ·EDTA] caused more extensive line broadening deeper within the protein but with the lower signal to noise of the lower peak heights. The data at 2 mm are shown in supplemental Fig. S3. The distance from the active site of the sites most protected by α1(V) THP is surprising and suggestive of exosites and/or nonspecific remote sites of contact.
FIGURE 5.
Location in the MMP-12 structure of α1(V) THP protection from line broadening by 1 mm Gd·EDTA. The solution structure of E219A-inactivated MMP-12 (36) (Protein Data Bank code 2POJ, model 1) is colored red at sites with backbone amide groups most protected by α1(V)436-450 THP with I1 m/I0,+THP-I1 m/I0, free > 0.4 in Fig. 4. The structure is colored orange at sites significantly protected with 0.4 > I1 m/I0,+THP-I1 m/I0, free > 0.15 in Fig. 4. The standard orientation of the backbone ribbon and surface plot in A and B, respectively, is rotated 55° forward in C to show the protection of the middle of the β-sheet and the neighboring “upper curve” of the S-shaped III-IV loop. The surfaces have been rendered for heavy atoms (without hydrogen atoms) with enough transparency to see the backbone ribbon within. Calcium ions are colored light gray, and zinc ions are medium gray. The arrow marks His-206 selected for mutagenesis.
Mutations That Decrease Specific Activity for α1(V) THP while Preserving General Activity—We sought to identify sequence determinants in the catalytic domain that may contribute to the activity of MMP-12 toward α1(V) THP. NMR mapping of another protein-protein interface with the same methods had rationally guided our mutagenesis directly and fruitfully to an unexpected hot spot (50) and guided our choice of mutations here as well. Two issues regarding MMP-12-specific activity toward α1(V) THP substrate need to be considered. First, the best characterized central region of the active site cleft is nearly identical in sequence among MMPs with widely disparate rates of turnover of this THP substrate. Second, NMR footprinting protection from the line broadening probe suggested prospective exosites based on the THP-dependent contacts at sites outside the catalytic cleft but in the catalytic domain (Figs. 4 and 5). We decided to mutate the most likely of the prospective exosites selected by three criteria: (i) protection by α1(V) THP from the NMR line broadening probe, (ii) a sequence differentiating MMP-12 from close MMP homologues that are much less active on this THP, and (iii) relative proximity to the active site. Three loci have their backbone protected by α1(V) THP and differ in sequence from the closest MMPs: sIII (Leu-162, Ala-164, and Phe-166), the V-B loop (Asp-200, His-206, and Thr-210), and Thr-239 of the B-C or S1′ specificity loop. We ignored the latter two threonines located in the active site cleft, the most distant sites of sIII, and Asp-200. We selected for mutagenesis both His-206 (Fig. 5, arrow) and Thr-205 (Fig. 2, arrow) because both lie outside the active site cleft but are nearest among the prospective exosites with distinctive sequence. Because the THP-protected backbone amide group of His-206 lies between the side chains of Thr-205 and His-206, either side chain might contact the THP. If α1(V) THP contacts the Thr-205 side chain, that could account for THP perturbation of the backbone amide chemical shift of Thr-205 (Fig. 2B, arrow). We mutated both residues to their sequence counterparts from the MMP-3 close homologue that is inactive upon the α1(V) THP. The resulting T205K/H206D double mutation retained 88% of wild type activity toward the general MMP substrate FS-6 (Table 2). However, the T205K/H206D mutation was 3.3-fold lower than wt in the second order rate constant kcat/Km for α1(V) THP (Fig. 6 and Table 2). Nearly all of this drop in specific activity was from the 3.15-fold higher Km of the T205K/H206D mutant for α1(V) THP (Table 2). Adding mutations of the Ser-207 and Gly-208 neighbors at the apex of the loop to their MMP-3 counterparts failed to change kcat/Km further. Thus, Thr-205 and His-206 of MMP-12 appear sufficient to form an important exosite in the catalytic domain of MMP-12 for α1(V) THP substrate. This is a subset of the larger chimeric swap of the entire V-B loop of MMP-1 to that of MMP-3 that demonstrated the V-B loop to be essential to collagenolysis by MMP-1 (4). The kcat/Km of MMP-12(T205K/H206D) toward either DQ-collagen I or DQ-collagen IV was 1.8-fold lower than wild type, suggesting this exosite to participate in collagenolysis by MMP-12 as well.4
TABLE 2.
Kinetic parameters for hydrolysis of α1(V)436-447 fTHP and general MMP substrate FS-6 at 25°C
|
MMP-12 variant
|
α1(V)436-447 fTHP
|
FS-6
|
||||
|---|---|---|---|---|---|---|
| kcat/Km | kcat | Km | kcat/Km | kcat | Km | |
| m−1s−1 | s−1 | μm | m−1s−1 | s−1 | μm | |
| Wild type | 55,400 ± 4,700 | 1.23 ± 0.10 | 22.2 ± 5.6 | 134,000 ± 4,000 | 17.4 ± 0.3 | 130 ± 3 |
| T205K/H206D | 16,700 ± 200 | 1.17 ± 0.20 | 70 ± 12 | 118,000 ± 300 | 6.9 ± 1.2 | 58.4 ± 9.9 |
| T205K/H206D/S207T/G208T | 17,700 ± 400 | NDa | ND | 120,000 ± 300 | 7.2 ± 0.4 | 60.0 ± 3.1 |
ND, not determined.
Implications for Packing and Unwinding of Triple Helices—A viable explanation of the protection data and mutagenesis data is that the triple helix of α1(V) THP bends to reach and pack against the V-B loop, III-IV loop, sIII, and sV. The bending would likely be accompanied by underwinding and potentially partial separation of chains of the triple helix, placing at least two of the chains such that they cover the remote protected sites. An alternative explanation of the α1(V) THP protection of surfaces outside the active site cleft would be additional but non-productive binding modes of rodlike triple helices. The reliance of MMP-12 on His-206 or Thr-205 at the remote exosite in the V-B loop for triple helical peptidase activity (Table 2) supports the bending of the triple helix rather than non-productive contacts with Thr-205/His-206. Thus, a model with bending of the triple helix seems more plausible. The thermal activation barrier of 13.7 kcal/mol that accompanies hydrolysis of α1(V)436-447 fTHP (Fig. 1C) and the kinetic lag phase for triple helical peptidase activity may be invested in the melting of the triple helix.
Where the GXY repeats of the triple helix are enriched in imino acids, namely Pro at X and hydroxyproline at Y, the triple helix is optimal in stability and structural, cylindrical regularity (66, 76-78). Such enrichment in imino acids is characteristic of the four triplets on the N-terminal side of the scissile bonds of interstitial collagens. The N-terminal side of the cleavage sites feature relatively small side chain volumes, Pro always present at the P3 position, and Pro never present at the P2 position from the cleavage site (79). In contrast, the four triplets on the C-terminal side of the scissile bond are depleted of imino acids in the X and Y positions, loosening or destabilizing the triple helix (79). The molecules in collagen model peptides and collagen fibrils predominantly have helical 7-fold symmetry (80, 81). Depletion of imino acids may cause the triple helix to become locally less tightly wound (66, 80). Suppose that triple helical peptides lie along the catalytic cleft with N to C terminus running from unprimed to primed subsites. Linear peptide substrates are observed in this orientation (8, 9), which is left to right in standard displays such as in Figs. 2B and 5 and supplemental Fig. S4. This orientation would place the stable N-terminal end of the triple helix intact into the wide funnel-shaped cleft of the unprimed subsites at left, accounting for the protections and chemical shift perturbations (Figs. 2 and 5, left). This orientation would place the destabilized C-terminal side of the scissile bond on the primed (right) side of the MMP active site. If this C-terminal region is destabilized enough to melt the triple helix at least locally, the partly melted chains may be able to “turn the corner” in the V-B loop to reach and protect many sites from Gd ·EDTA.
The extensive protection of the V-B loop by α1(V) THP strongly suggests that one or more of its chains packs against one or more locations in this loop. For the THP to protect the N-terminal end of the V-B loop (Asp-200 through His-206), the THP must bend from the active site cleft at a right angle around the C-terminal end of the V-B loop. This proposed right angle turn would be inconsistent with a regular and rodlike triple helix. The protection of the S-shaped III-IV loop of MMP-12 by α1(V) THP (Figs. 4 and 5) suggests that a chain of the THP may also drape across the III-IV loop. Separation of chains of the THP may account for protections occurring on both the V-B and III-IV loops. Most surprising is the protection of a remote pocket formed among residues of the upper lobe of the III-IV loop (Gly-166 and His-168), sIII (Val-162 to Leu-164), sV (Ala-195g, His-196, and Phe-197), and even sI (Asn-119) (Fig. 5C). (The wall of this pocket contains the two THP-protected histidine ligands of the structural zinc between the III-IV loop and sV.) If the α1(V) THP were to extend from the active site and wrap all the way around the III-IV loop, the THP might protect this remote pocket directly. Such extensive bending of a chain of the α1(V) THP could promote melting of the triple helix. A non-productive binding mode in which some intact triple helix covers this pocket is an alternative hypothesis for the protection observed.
One speculative model that accounts for the protections and orients the THP with bending as discussed above is depicted in supplemental Fig. S4. The model illustrates that bending of the triple helix around the catalytic domain could largely account for the protection of its surface by α1(V) THP. Such bending would be conducive to separating the strands of the triple helix (supplemental Fig. S4). Like bending of DNA promotes underwinding and may facilitate localized strand separation in initiation of transcription (82), bending of the collagen triple helix about the MMP catalytic domain might also facilitate underwinding and separation of its chains at less stable loci in the triple helix. A path that collagens might traverse from the active site of a gelatinase to the collagen and gelatin binding site identified in fibronectin module 2 of MMP-9 (83, 84) can be hypothesized to bend analogously around the primed end of the catalytic cleft as well as around fibronectin module 2.
Comparison of Specificity and Collagenolysis of MMP-12 and the Gelatinases—MMP-12 hydrolyzes collagens IV and V, α1(V) THP, gelatin, and elastin (28, 72, 85-87) as do the gelatinases (11, 88-91). Both MMP-12 and MMP-2 hydrolyze DQ-collagens I and IV. Full-length MMP-2, -9, and -12 are remarkably similar in efficiency of turnover of α1(V) THP with apparent kcat/Km spanning a range of only 22% among them (Table 1). The C-terminal hemopexin-like domains of MMP-9 and -12 clearly enhance Km and kcat/Km (Table 1). Stoichiometric binding of inhibited MMP-2 almost completely unwinds collagen I at 37 °C, apparently by way of the fibronectin-like inserts (92). In contrast, the catalytic domain of MMP-12 may be sufficient for partial unwinding of α1(V) THP at 26 °C in the absence of the fibronectin-like modules of the gelatinases. The hydrolysis of α1(V)436-447 fTHP by MMP-12 differs from the gelatinases in having a longer lag phase and a shifted preference in site of cleavage. As the concentration of α1(V)436-447 fTHP is raised through the low micromolar range, the catalysis of MMP-12 results in smaller amplitudes of fluorescence increase than the gelatinases. Perhaps α1(V)436-447 fTHP might form small soluble aggregates that impede and complicate hydrolysis by MMP-12 but not the hydrolysis by gelatinases. Higher order self-association has been reported for some THPs (93). Alternatively MMP-12 might be more sensitive to product inhibition. Thus, in addition to its lack of fibronectin-like modules, MMP-12 exhibits altered kinetic behavior compared with gelatinases that may differentiate them in some respects of their mechanisms of unwinding and hydrolysis of the α1(V) THP substrate.
Given the differences, it need not be surprising that MMP-12 prefers to hydrolyze the α1(V) THP at a different site than MMP-9 does. The Glu↓Gln scissile bond preferred by MMP-12 is cleaved by MMP-2 also but is four residues closer to the C terminus than the Gly↓Val linkage attacked by both MMP-9 and MMP-2. The Glu↓Gln site lies in the center of the imino-deficient sequence that is more easily melted at the time of cleavage. The cleavage sites of the gelatinases tend to have Gly at P4, Pro at P3, Gly at P1, Leu at P1′, and Gly at P3′ with frequencies of about 30% and greater according to the MEROPS data base (94). This pattern corresponds to the collagen triple repeat sequence of Gly-Pro-Xaa except at P1′ where Leu is much preferred over Pro. Among these preferences, MMP-12 shares only the preferences of Pro at P3 and Leu at P1′ as do all of the mammalian MMPs characterized (94). The distinctive hydrolysis of the VGE↓Q site in α1(V) THP and its VGE↓K(Dnp) counterpart in fluorogenic α1(V) THP by MMP-12 is consistent with its known cleavage sites with Glu at P1 in 16% of cases and Val at P3 in 12% of cases; these are much higher frequencies than for the gelatinases (94). MMP-12 is more tolerant of bulky groups in P1′. Consequently MMP-12 exerts an order of magnitude higher kcat/Km for the substrate NFF-2 with bulky norvaline in P1′ (95) than either of the gelatinases (96). Tolerance of bulky groups at P1′ (87) by MMP-12 may accommodate the Lys(Dnp) at P1′ of α1(V)436-447 fTHP.
Summary—MMP-12 joins the gelatinases in actively digesting the triple helical peptide derived from the collagen V site that they cleave (Fig. 1 and Table 1). The C-terminal domains of MMP-9 and -12 increase their second order rate constants (kcat/Km) toward this substrate by improving Km values. This implies that the C-terminal domains may contribute favorable contacts to this THP substrate or guide the binding of α1(V) THP. The hypothesis of bending and partial unwinding of the imino-depleted segment of α1(V)436-450 THP could account for the novel and complex distribution of MMP-12 surfaces it protects and for the effect of the T205K/H206D lesion. The exosite at Thr-205 and His-206 in the V-B loop is necessary for the full specific activity of MMP-12 for α1(V)436-447 fTHP but not for a general substrate of MMPs. This corroborates the need of MMP-1 for the V-B loop for collagenolysis (4) and pinpoints an exosite to the N-terminal end of the V-B loop. NMR footprinting identified prospective exosites in the catalytic domain that contact α1(V)436-450 THP. The novel exosites principally appear in the V-B loop, the S-shaped III-IV loop that binds zinc and calcium, and a pocket it forms together with β-strands sIII and sV (Fig. 5). These surfaces of MMPs may merit investigation as potential exosites for collagen interaction in addition to exosites on the C-terminal hemopexin domain and fibronectin-like insert domains.
Supplementary Material
This work was supported, in whole or in part, by National Institutes of Health Grants R01 GM57289 (to S. R. V.), GM008396 (training grant support for M. O. P.), and R01 CA98799 (to G. B. F.). This work was also supported by American Heart Association Grant 0455885Z. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1-S4.
Footnotes
The abbreviations used are: MMP, matrix metalloproteinase; hA-hC, helices A-C; MALDI, matrix-assisted laser desorption ionization; TOF, time-of-flight; sI-sV, β-strands I-V; THP, triple helical peptide; fTHP, fluorescent triple helical peptide; TROSY, transverse relaxation optimized spectroscopy; wt, wild type; Dnp, 2,4-dinitrophenyl; Mca, 7-methoxycoumarin-4-acetyl.
M. O. Palmier, R. Bhaskaran, and S. R. Van Doren, manuscript in preparation.
References
- 1.Woessner, J. F., Jr., and Nagase, H. (2000) Matrix Metalloproteinases and TIMPs, pp. 126-129, Oxford University Press, New York
- 2.Sternlicht, M. D., and Werb, Z. (2001) Annu. Rev. Cell Dev. Biol. 17 463-516 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hu, J., Van den Steen, P. E., Sang, Q. X., and Opdenakker, G. (2007) Nat. Rev. Drug Discov. 6 480-498 [DOI] [PubMed] [Google Scholar]
- 4.Chung, L., Shimokawa, K., Dinakarpandian, D., Grams, F., Fields, G. B., and Nagase, H. (2000) J. Biol. Chem. 275 29610-29617 [DOI] [PubMed] [Google Scholar]
- 5.Pelman, G. R., Morrison, C. J., and Overall, C. M. (2005) J. Biol. Chem. 280 2370-2377 [DOI] [PubMed] [Google Scholar]
- 6.Minond, D., Lauer-Fields, J. L., Cudic, M., Overall, C. M., Pei, D., Brew, K., Visse, R., Nagase, H., and Fields, G. B. (2006) J. Biol. Chem. 281 38302-38313 [DOI] [PubMed] [Google Scholar]
- 7.Chung, L., Dinakarpandian, D., Yoshida, N., Lauer-Fields, J. L., Fields, G. B., Visse, R., and Nagase, H. (2004) EMBO J. 23 3020-3030 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Maletta, M., and Yeo, K. J. (2006) Angew. Chem. Int. Ed. Engl. 45 7952-7955 [DOI] [PubMed] [Google Scholar]
- 9.Lang, R., Kocourek, A., Braun, M., Tschesche, H., Huber, R., Bode, W., and Maskos, K. (2001) J. Mol. Biol. 312 731-742 [DOI] [PubMed] [Google Scholar]
- 10.Lauer-Fields, J. L., Tuzinski, K. A., Shimokawa, K., Nagase, H., and Fields, G. B. (2000) J. Biol. Chem. 275 13282-13290 [DOI] [PubMed] [Google Scholar]
- 11.Lauer-Fields, J. L., Sritharan, T., Stack, M. S., Nagase, H., and Fields, G. B. (2003) J. Biol. Chem. 278 18140-18145 [DOI] [PubMed] [Google Scholar]
- 12.Lauer-Fields, J. L., Broder, T., Sritharan, T., Chung, L., Nagase, H., and Fields, G. B. (2001) Biochemistry 40 5795-5803 [DOI] [PubMed] [Google Scholar]
- 13.Minond, D., Lauer-Fields, J. L., Nagase, H., and Fields, G. B. (2004) Biochemistry 43 11474-11481 [DOI] [PubMed] [Google Scholar]
- 14.Sun, H. B., Smith, G. N., Jr., Hasty, K. A., and Yokota, H. (2000) Anal. Biochem. 283 153-158 [DOI] [PubMed] [Google Scholar]
- 15.Saffarian, S., Collier, I. E., Marmer, B. L., Elson, E. L., and Goldberg, G. (2004) Science 306 108-111 [DOI] [PubMed] [Google Scholar]
- 16.Overall, C. M. (2002) Mol. Biotechnol. 22 51-86 [DOI] [PubMed] [Google Scholar]
- 17.Lauer-Fields, J. L., Minond, D., Sritharan, T., Kashiwagi, M., Nagase, H., and Fields, G. B. (2007) J. Biol. Chem. 282 142-150 [DOI] [PubMed] [Google Scholar]
- 18.Minond, D., Lauer-Fields, J. L., Cudic, M., Overall, C. M., Pei, D., Brew, K., Moss, M. L., and Fields, G. B. (2007) Biochemistry 46 3724-3733 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Galis, Z. S., Sukhova, G. K., Lark, M. W., and Libby, P. (1994) J. Clin. Investig. 94 2493-2503 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Sukhova, G. K., Schonbeck, U., Rabkin, E., Schoen, F. J., Poole, A. R., Billinghurst, R. C., and Libby, P. (1999) Circulation 99 2503-2509 [DOI] [PubMed] [Google Scholar]
- 21.Libby, P., and Aikawa, M. (2002) Nat. Med. 8 1257-1262 [DOI] [PubMed] [Google Scholar]
- 22.Shapiro, S. D. (1999) Thromb. Haemostasis 82 846-849 [PubMed] [Google Scholar]
- 23.Matsumoto, S., Kobayashi, T., Katoh, M., Saito, S., Ikeda, Y., Kobori, M., Masuho, Y., and Watanabe, T. (1998) Am J. Pathol. 153 109-119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Liang, J., Liu, E., Yu, Y., Kitajima, S., Koike, T., Jin, Y., Morimoto, M., Hatakeyama, K., Asada, Y., Watanabe, T., Sasaguri, Y., Watanabe, S., and Fan, J. (2006) Circulation 113 1993-2001 [DOI] [PubMed] [Google Scholar]
- 25.Johnson, J. L. (2007) Expert Rev. Cardiovasc. Ther. 5 265-282 [DOI] [PubMed] [Google Scholar]
- 26.Johnson, J. L., George, S. J., Newby, A. C., and Jackson, C. L. (2005) Proc. Natl. Acad. Sci. U. S. A. 102 15575-15580 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Wang, X., Liang, J., Koike, T., Sun, H., Ichikawa, T., Kitajima, S., Morimoto, M., Shikama, H., Watanabe, T., Sasaguri, Y., and Fan, J. (2004) Am. J. Pathol. 165 1375-1383 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Shapiro, S. D., Kobayashi, D. K., and Ley, T. J. (1993) J. Biol. Chem. 268 23824-23829 [PubMed] [Google Scholar]
- 29.Maskos, K. (2005) Biochimie (Paris) 87 249-263 [DOI] [PubMed] [Google Scholar]
- 30.Nar, H., Werle, K., Bauer, M. M., Dollinger, H., and Jung, B. (2001) J. Mol. Biol. 312 743-751 [DOI] [PubMed] [Google Scholar]
- 31.Bertini, I., Calderone, V., Cosenza, M., Fragai, M., Lee, Y. M., Luchinat, C., Mangani, S., Terni, B., and Turano, P. (2005) Proc. Natl. Acad. Sci. U. S. A. 102 5334-5339 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Bertini, I., Calderone, V., Fragai, M., Giachetti, A., Loconte, M., Luchinat, C., Maletta, M., Nativi, C., and Yeo, K. J. (2007) J. Am. Chem. Soc. 129 2466-2475 [DOI] [PubMed] [Google Scholar]
- 33.Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani, S., and Terni, B. (2003) Angew. Chem. Int. Ed. Engl. 42 2673-2676 [DOI] [PubMed] [Google Scholar]
- 34.Mannino, C., Nievo, M., Machetti, F., Papakyriakou, A., Calderone, V., Fragai, M., and Guarna, A. (2006) Bioorg. Med. Chem. 14 7392-7403 [DOI] [PubMed] [Google Scholar]
- 35.Morales, R., Perrier, S., Florent, J. M., Beltra, J., Dufour, S., De Mendez, I., Manceau, P., Tertre, A., Moreau, F., Compere, D., Dublanchet, A. C., and O'Gara, M. (2004) J. Mol. Biol. 341 1063-1076 [DOI] [PubMed] [Google Scholar]
- 36.Bhaskaran, R., Palmier, M. O., Bagegni, N., Liang, X., and Van Doren, S. R. (2007) J. Mol. Biol. 374 1333-1344 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Garrett, D. S., Seok, Y. J., Peterkofsky, A., Gronenborn, A. M., and Clore, G. M. (1999) Nat. Struct. Biol. 6 166-173 [DOI] [PubMed] [Google Scholar]
- 38.Linsenmayer, T. F., Fitch, J. M., Gordon, M. K., Cai, C. X., Igoe, F., Marchant, J. K., and Birk, D. E. (1998) Prog. Retin. Eye Res. 17 231-265 [DOI] [PubMed] [Google Scholar]
- 39.Linsenmayer, T. F., Gibney, E., Igoe, F., Gordon, M. K., Fitch, J. M., Fessler, L. I., and Birk, D. E. (1993) J. Cell Biol. 121 1181-1189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Fessler, J. H., and Fessler, L. I. (1987) in Structure and Function of Collagen Types (Mayne, R., and Burgeson, R. E., eds) pp. 81-103, Academic Press, New York
- 41.Niyibizi, C., and Eyre, D. R. (1994) Eur. J. Biochem. 224 943-950 [DOI] [PubMed] [Google Scholar]
- 42.Sage, H., and Bornstein, P. (1979) Biochemistry 18 3815-3822 [DOI] [PubMed] [Google Scholar]
- 43.Liotta, L. A., Lanzer, W. L., and Garbisa, S. (1981) Biochem. Biophys. Res. Commun. 98 184-190 [DOI] [PubMed] [Google Scholar]
- 44.Hibbs, M. S., Hasty, K. A., Seyer, J. M., Kang, A. H., and Mainardi, C. L. (1985) J. Biol. Chem. 260 2493-2500 [PubMed] [Google Scholar]
- 45.Rich, E. A., Seyer, J. M., Kang, A. H., and Mainardi, C. L. (1983) Am. Rev. Respir. Dis. 128 166-169 [DOI] [PubMed] [Google Scholar]
- 46.Niyibizi, C., Chan, R., Wu, J. J., and Eyre, D. (1994) Biochem. Biophys. Res. Commun. 202 328-333 [DOI] [PubMed] [Google Scholar]
- 47.Arumugam, S., Hemme, C. L., Yoshida, N., Suzuki, K., Nagase, H., Berjanskii, M., Wu, B., and Van Doren, S. R. (1998) Biochemistry 37 9650-9657 [DOI] [PubMed] [Google Scholar]
- 48.Arumugam, S., and Van Doren, S. R. (2003) Biochemistry 42 7950-7958 [DOI] [PubMed] [Google Scholar]
- 49.Gao, G., Prutzman, K. C., King, M. L., Scheswohl, D. M., DeRose, E. F., London, R. E., Schaller, M. D., and Campbell, S. L. (2004) J. Biol. Chem. 279 8441-8451 [DOI] [PubMed] [Google Scholar]
- 50.Garimella, R., Liu, X., Qiao, W., Liang, X., Zuiderweg, E. R., Riley, M. I., and Van Doren, S. R. (2006) Biochemistry 45 6917-6929 [DOI] [PubMed] [Google Scholar]
- 51.Palmier, M., and Van Doren, S. R. (2007) Anal. Biochem. 371 43-51 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Williams, J. W., and Morrison, J. F. (1979) Methods Enzymol. 63 437-467 [DOI] [PubMed] [Google Scholar]
- 53.Grobelny, D., Poncz, L., and Galardy, R. E. (1992) Biochemistry 31 7152-7154 [DOI] [PubMed] [Google Scholar]
- 54.Niedzwiecki, L., Teahan, J., Harrison, R. K., and Stein, R. L. (1992) Biochemistry 31 12618-12623 [DOI] [PubMed] [Google Scholar]
- 55.Neumann, U., Kubota, H., Frei, K., Ganu, V., and Leppert, D. (2004) Anal. Biochem. 328 166-173 [DOI] [PubMed] [Google Scholar]
- 56.Cha, J., and Auld, D. S. (1997) Biochemistry 36 16019-16024 [DOI] [PubMed] [Google Scholar]
- 57.Crabbe, T., Zucker, S., Cockett, M. I., Willenbrock, F., Tickle, S., O'Connell, J. P., Scothern, J. M., Murphy, G., and Docherty, A. J. (1994) Biochemistry 33 6684-6690 [DOI] [PubMed] [Google Scholar]
- 58.Bhaskaran, R., and Van Doren, S. R. (2006) J. Biomol. NMR 36 Suppl. 1, 55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Parkar, A. A., Stow, M. D., Smith, K., Panicker, A. K., Guilloteau, J. P., Jupp, R., and Crowe, S. J. (2000) Protein Expr. Purif. 20 152-161 [DOI] [PubMed] [Google Scholar]
- 60.Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) J. Biomol. NMR 6 277-293 [DOI] [PubMed] [Google Scholar]
- 61.Goddard, T. D., and Kneller, D. G. (2000) SPARKY, 3rd Ed., University of California, San Francisco
- 62.Mori, S., Abeygunawardana, C., O'Neil Johnson, M., and Van Zijl, P. C. M. (1995) J. Magn. Reson. B 108 94-98 [DOI] [PubMed] [Google Scholar]
- 63.Pervushin, K., Riek, R., Wider, G., and Wuthrich, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94 12366-12371 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Ferreon, J. C., and Hilser, V. J. (2003) Protein Sci. 12 982-996 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Lian, L., and Roberts, G. C. K. (1993) in NMR of Macromolecules. A Practical Approach (Roberts, G. C. K., ed) pp. 153-182, Oxford University Press, Oxford
- 66.Kramer, R. Z., Bella, J., Mayville, P., Brodsky, B., and Berman, H. M. (1999) Nat. Struct. Biol. 6 454-457 [DOI] [PubMed] [Google Scholar]
- 67.Koradi, R., Billeter, M., and Wüthrich, K. (1996) J. Mol. Graph. 14 51-55 [DOI] [PubMed] [Google Scholar]
- 68.Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18 2714-2723 [DOI] [PubMed] [Google Scholar]
- 69.DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA
- 70.Lauer-Fields, J. L., and Fields, G. B. (2002) Biol. Chem. 383 1095-1105 [DOI] [PubMed] [Google Scholar]
- 71.Lauer-Fields, J. L., Kele, P., Sui, G., Nagase, H., Leblanc, R. M., and Fields, G. B. (2003) Anal. Biochem. 321 105-115 [DOI] [PubMed] [Google Scholar]
- 72.Fu, J. Y., Lyga, A., Shi, H., Blue, M. L., Dixon, B., and Chen, D. (2001) Protein Expr. Purif. 21 268-274 [DOI] [PubMed] [Google Scholar]
- 73.Aimes, R. T., and Quigley, J. P. (1995) J. Biol. Chem. 270 5872-5876 [DOI] [PubMed] [Google Scholar]
- 74.Sakakura, M., Noba, S., Luchette, P. A., Shimada, I., and Prosser, R. S. (2005) J. Am. Chem. Soc. 127 5826-5832 [DOI] [PubMed] [Google Scholar]
- 75.Takeda, M., Terasawa, H., Sakakura, M., Yamaguchi, Y., Kajiwara, M., Kawashima, H., Miyasaka, M., and Shimada, I. (2003) J. Biol. Chem. 278 43550-43555 [DOI] [PubMed] [Google Scholar]
- 76.Sakakibara, S., Inouye, K., Shudo, K., Kishida, Y., Kobayashi, Y., and Prockop, D. J. (1973) Biochim. Biophys. Acta 303 198-202 [DOI] [PubMed] [Google Scholar]
- 77.Long, C. G., Braswell, E., Zhu, D., Apigo, J., Baum, J., and Brodsky, B. (1993) Biochemistry 32 11688-11695 [DOI] [PubMed] [Google Scholar]
- 78.Bella, J., Eaton, M., Brodsky, B., and Berman, H. M. (1994) Science 266 75-81 [DOI] [PubMed] [Google Scholar]
- 79.Fields, G. B. (1991) J. Theor. Biol. 153 585-602 [DOI] [PubMed] [Google Scholar]
- 80.Okuyama, K., Wu, G., Jiravanichanun, N., Hongo, C., and Noguchi, K. (2006) Biopolymers 84 421-432 [DOI] [PubMed] [Google Scholar]
- 81.Okuyama, K., Xu, X., Iguchi, M., and Noguchi, K. (2006) Biopolymers 84 181-191 [DOI] [PubMed] [Google Scholar]
- 82.Coulombe, B., and Burton, Z. F. (1999) Microbiol. Mol. Biol. Rev. 63 457-478 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Collier, I. E., Krasnov, P. A., Strongin, A. Y., Birkedal-Hansen, H., and Goldberg, G. I. (1992) J. Biol. Chem. 267 6776-6781 [PubMed] [Google Scholar]
- 84.Elkins, P. A., Ho, Y. S., Smith, W. W., Janson, C. A., D'Alessio, K. J., Mc-Queney, M. S., Cummings, M. D., and Romanic, A. M. (2002) Acta Crystallogr. Sect. D Biol. Crystallogr. 58 1182-1192 [DOI] [PubMed] [Google Scholar]
- 85.Shipley, J. M., Doyle, G. A., Fliszar, C. J., Ye, Q. Z., Johnson, L. L., Shapiro, S. D., Welgus, H. G., and Senior, R. M. (1996) J. Biol. Chem. 271 4335-4341 [DOI] [PubMed] [Google Scholar]
- 86.Chandler, S., Cossins, J., Lury, J., and Wells, G. (1996) Biochem. Biophys. Res. Commun. 228 421-429 [DOI] [PubMed] [Google Scholar]
- 87.Gronski, T. J., Jr., Martin, R. L., Kobayashi, D. K., Walsh, B. C., Holman, M. C., Huber, M., Van Wart, H. E., and Shapiro, S. D. (1997) J. Biol. Chem. 272 12189-12194 [DOI] [PubMed] [Google Scholar]
- 88.Murphy, G., Reynolds, J. J., Bretz, U., and Baggiolini, M. (1982) Biochem. J. 203 209-221 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Murphy, G., McAlpine, C. G., Poll, C. T., and Reynolds, J. J. (1985) Biochim. Biophys. Acta 831 49-58 [DOI] [PubMed] [Google Scholar]
- 90.Morodomi, T., Ogata, Y., Sasaguri, Y., Morimatsu, M., and Nagase, H. (1992) Biochem. J. 285 603-611 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., and Hayakawa, T. (1992) J. Biol. Chem. 267 21712-21719 [PubMed] [Google Scholar]
- 92.Gioia, M., Monaco, S., Fasciglione, G. F., Coletti, A., Modesti, A., Marini, S., and Coletta, M. (2007) J. Mol. Biol. 368 1101-1113 [DOI] [PubMed] [Google Scholar]
- 93.Brodsky, B., Thiagarajan, G., Madhan, B., and Kar, K. (2008) Biopolymers 89 345-353 [DOI] [PubMed] [Google Scholar]
- 94.Rawlings, N. D., Morton, F. R., Kok, C. Y., Kong, J., and Barrett, A. J. (2008) Nucleic Acids Res. 36 D320-D325 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Park, H. I., Ni, J., Gerkema, F. E., Liu, D., Belozerov, V. E., and Sang, Q. X. (2000) J. Biol. Chem. 275 20540-20544 [DOI] [PubMed] [Google Scholar]
- 96.Nagase, H., Fields, C. G., and Fields, G. B. (1994) J. Biol. Chem. 269 20952-20957 [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.







